1.Enhancing Clerkship through a Ubiquitous Portfolio System: Design, Development, Implementation, and Dissemination
Bo Young YOON ; Younseok LEE ; Sejung KWON ; Ikseon CHOI ; Jong-Tae LEE
Korean Medical Education Review 2025;27(1):26-39
This paper describes the design, development, and implementation of a ubiquitous portfolio (u-portfolio) system aimed at enhancing clinical clerkship education at Inje University College of Medicine from 2016 to 2020. This developmental research employed involved a literature review of 69 papers on electronic portfolios (1990–2013), and as well as a series of focus group interviews and surveys with key stakeholders during the iterative design, evaluation, and revision process. The literature analysis revealed three main purposes of e-portfolios (learning, assessment, and showcase) and nine key elements for a multi-purpose e-portfolio (e.g., quality of student reflection, postgraduate continuous learning, and timely and frequent feedback). The system evolved from paper-based portfolios to address the standardization of students’ clerkship experiences across five teaching hospitals, incorporating competency-based education and enabling efficient data management to promote student learning, assessment, and feedback. Key challenges in transitioning from paper to electronic portfolios included infrastructure issues, user adaptation, and assessment standardization. The resulting u-portfolio system, which allowed the seamless integration of mobile devices, emphasized five core functions: enhanced real-time feedback, transparent evaluation with rubrics, improved reflection quality, real-time assessment and tracking, and mapping between learning and competency achievements. Initially implemented in the internal medicine clerkship in 2016, the system was gradually expanded to all core clerkships by 2018. The success of this system led to its adoption by 19 medical schools through a consortium organized by the Korea Association of Medical Colleges, with 31 schools now collaborating to enhance clerkships through the u-portfolio system.
2.Enhancing Clerkship through a Ubiquitous Portfolio System: Design, Development, Implementation, and Dissemination
Bo Young YOON ; Younseok LEE ; Sejung KWON ; Ikseon CHOI ; Jong-Tae LEE
Korean Medical Education Review 2025;27(1):26-39
This paper describes the design, development, and implementation of a ubiquitous portfolio (u-portfolio) system aimed at enhancing clinical clerkship education at Inje University College of Medicine from 2016 to 2020. This developmental research employed involved a literature review of 69 papers on electronic portfolios (1990–2013), and as well as a series of focus group interviews and surveys with key stakeholders during the iterative design, evaluation, and revision process. The literature analysis revealed three main purposes of e-portfolios (learning, assessment, and showcase) and nine key elements for a multi-purpose e-portfolio (e.g., quality of student reflection, postgraduate continuous learning, and timely and frequent feedback). The system evolved from paper-based portfolios to address the standardization of students’ clerkship experiences across five teaching hospitals, incorporating competency-based education and enabling efficient data management to promote student learning, assessment, and feedback. Key challenges in transitioning from paper to electronic portfolios included infrastructure issues, user adaptation, and assessment standardization. The resulting u-portfolio system, which allowed the seamless integration of mobile devices, emphasized five core functions: enhanced real-time feedback, transparent evaluation with rubrics, improved reflection quality, real-time assessment and tracking, and mapping between learning and competency achievements. Initially implemented in the internal medicine clerkship in 2016, the system was gradually expanded to all core clerkships by 2018. The success of this system led to its adoption by 19 medical schools through a consortium organized by the Korea Association of Medical Colleges, with 31 schools now collaborating to enhance clerkships through the u-portfolio system.
3.Enhancing Clerkship through a Ubiquitous Portfolio System: Design, Development, Implementation, and Dissemination
Bo Young YOON ; Younseok LEE ; Sejung KWON ; Ikseon CHOI ; Jong-Tae LEE
Korean Medical Education Review 2025;27(1):26-39
This paper describes the design, development, and implementation of a ubiquitous portfolio (u-portfolio) system aimed at enhancing clinical clerkship education at Inje University College of Medicine from 2016 to 2020. This developmental research employed involved a literature review of 69 papers on electronic portfolios (1990–2013), and as well as a series of focus group interviews and surveys with key stakeholders during the iterative design, evaluation, and revision process. The literature analysis revealed three main purposes of e-portfolios (learning, assessment, and showcase) and nine key elements for a multi-purpose e-portfolio (e.g., quality of student reflection, postgraduate continuous learning, and timely and frequent feedback). The system evolved from paper-based portfolios to address the standardization of students’ clerkship experiences across five teaching hospitals, incorporating competency-based education and enabling efficient data management to promote student learning, assessment, and feedback. Key challenges in transitioning from paper to electronic portfolios included infrastructure issues, user adaptation, and assessment standardization. The resulting u-portfolio system, which allowed the seamless integration of mobile devices, emphasized five core functions: enhanced real-time feedback, transparent evaluation with rubrics, improved reflection quality, real-time assessment and tracking, and mapping between learning and competency achievements. Initially implemented in the internal medicine clerkship in 2016, the system was gradually expanded to all core clerkships by 2018. The success of this system led to its adoption by 19 medical schools through a consortium organized by the Korea Association of Medical Colleges, with 31 schools now collaborating to enhance clerkships through the u-portfolio system.
4.Enhancing Clerkship through a Ubiquitous Portfolio System: Design, Development, Implementation, and Dissemination
Bo Young YOON ; Younseok LEE ; Sejung KWON ; Ikseon CHOI ; Jong-Tae LEE
Korean Medical Education Review 2025;27(1):26-39
This paper describes the design, development, and implementation of a ubiquitous portfolio (u-portfolio) system aimed at enhancing clinical clerkship education at Inje University College of Medicine from 2016 to 2020. This developmental research employed involved a literature review of 69 papers on electronic portfolios (1990–2013), and as well as a series of focus group interviews and surveys with key stakeholders during the iterative design, evaluation, and revision process. The literature analysis revealed three main purposes of e-portfolios (learning, assessment, and showcase) and nine key elements for a multi-purpose e-portfolio (e.g., quality of student reflection, postgraduate continuous learning, and timely and frequent feedback). The system evolved from paper-based portfolios to address the standardization of students’ clerkship experiences across five teaching hospitals, incorporating competency-based education and enabling efficient data management to promote student learning, assessment, and feedback. Key challenges in transitioning from paper to electronic portfolios included infrastructure issues, user adaptation, and assessment standardization. The resulting u-portfolio system, which allowed the seamless integration of mobile devices, emphasized five core functions: enhanced real-time feedback, transparent evaluation with rubrics, improved reflection quality, real-time assessment and tracking, and mapping between learning and competency achievements. Initially implemented in the internal medicine clerkship in 2016, the system was gradually expanded to all core clerkships by 2018. The success of this system led to its adoption by 19 medical schools through a consortium organized by the Korea Association of Medical Colleges, with 31 schools now collaborating to enhance clerkships through the u-portfolio system.
5.Enhancing Clerkship through a Ubiquitous Portfolio System: Design, Development, Implementation, and Dissemination
Bo Young YOON ; Younseok LEE ; Sejung KWON ; Ikseon CHOI ; Jong-Tae LEE
Korean Medical Education Review 2025;27(1):26-39
This paper describes the design, development, and implementation of a ubiquitous portfolio (u-portfolio) system aimed at enhancing clinical clerkship education at Inje University College of Medicine from 2016 to 2020. This developmental research employed involved a literature review of 69 papers on electronic portfolios (1990–2013), and as well as a series of focus group interviews and surveys with key stakeholders during the iterative design, evaluation, and revision process. The literature analysis revealed three main purposes of e-portfolios (learning, assessment, and showcase) and nine key elements for a multi-purpose e-portfolio (e.g., quality of student reflection, postgraduate continuous learning, and timely and frequent feedback). The system evolved from paper-based portfolios to address the standardization of students’ clerkship experiences across five teaching hospitals, incorporating competency-based education and enabling efficient data management to promote student learning, assessment, and feedback. Key challenges in transitioning from paper to electronic portfolios included infrastructure issues, user adaptation, and assessment standardization. The resulting u-portfolio system, which allowed the seamless integration of mobile devices, emphasized five core functions: enhanced real-time feedback, transparent evaluation with rubrics, improved reflection quality, real-time assessment and tracking, and mapping between learning and competency achievements. Initially implemented in the internal medicine clerkship in 2016, the system was gradually expanded to all core clerkships by 2018. The success of this system led to its adoption by 19 medical schools through a consortium organized by the Korea Association of Medical Colleges, with 31 schools now collaborating to enhance clerkships through the u-portfolio system.
6.Evaluation of Vancomycin TDM Strategies: Prediction and Prevention of Kidney Injuries Based on Vancomycin TDM Results
Byungwook KIM ; Sejung HWANG ; Eunjeong HEO ; Hyung-sook KIM ; Jongtak JUNG ; Eu Suk KIM ; Hong Bin KIM ; Kyunghoon LEE ; Jeong Su PARK ; Junghan SONG ; Joon Hee LEE ; Jae-Yong CHUNG ; Kyoung-Ho SONG ; Seonghae YOON
Journal of Korean Medical Science 2023;38(14):e101-
The current guidelines for therapeutic drug monitoring (TDM) of vancomycin suggest a target 24-hour area under the curve (AUC 0-24 ) of 400 to 600 mg*h/L for serious methicillinresistant Staphylococcus aureus infections. In this study, the predictabilities of acute kidney injury (AKI) of various TDM target parameters, target levels, and sampling methods were evaluated in patients who underwent TDM from January 2020 to December 2020. The AUC 0-24 and trough values were calculated by both one- and two-point sampling methods, and were evaluated for the predictability of AKI. Among the AUC 0-24 cutoff comparisons, the threshold value of 500 mg*h/L in the two sampling methods was statistically significant (P = 0.042) when evaluated for the predictability of AKI. Analysis by an receiver operating characteristic curve estimated an AUC 0-24 cutoff value of 563.45 mg*h/L as a predictor of AKI, and was proposed as the upper limit of TDM target.
7.Population Pharmacokinetic− Pharmacodynamic Modeling of Carvedilol to Evaluate the Effect of Cytochrome P450 2D6 Genotype on the Heart Rate Reduction
Sejung HWANG ; Soyoung LEE ; Jangsoo YOON ; Jae-Yong CHUNG
Journal of Korean Medical Science 2023;38(22):e173-
Background:
Carvedilol is a beta-adrenergic receptor antagonist primarily metabolized by cytochromes P450 (CYP) 2D6. This study established a carvedilol population pharmacokinetic (PK)–pharmacodynamic (PD) model to describe the effects of CYP2D6 genetic polymorphisms on the inter-individual variability of PK and PD.
Methods:
The PK–PD model was developed from a clinical study conducted on 21 healthy subjects divided into three CYP2D6 phenotype groups, with six subjects in the extensive metabolizer (EM, *1/*1, *1/*2), seven in the intermediate metabolizer-1 (IM-1, *1/*10, *2/*10), and eight in the intermediate metabolizer-2 (IM-2, *10/*10) groups. The PK–PD model was sequentially developed, and the isoproterenol-induced heart rate changes were used to establish the PD model. A direct effect response and inhibitory E max model were used to develop a carvedilol PK–PD model.
Results:
The carvedilol PK was well described by a two-compartment model with zeroorder absorption, lag time, and first-order elimination. The carvedilol clearance in the CYP2D6*10/*10 group decreased by 32.8% compared with the other groups. The inhibitory concentration of carvedilol estimated from the final PK–PD model was 16.5 ng/mL regardless of the CYP2D6 phenotype.
Conclusion
The PK–PD model revealed that the CYP2D6 genetic polymorphisms were contributed to the inter-individual variability of carvedilol PK, but not PD.
8.Assessment of the Clinical Heterogeneity of Kawasaki Disease Using Genetic Variants of BLK and FCGR2A
Bo Kyung SIM ; Hyein PARK ; Jae Jung KIM ; Sin Weon YUN ; Jeong Jin YU ; Kyung Lim YOON ; Kyung Yil LEE ; Hong Ryang KIL ; Gi Beom KIM ; Myung Ki HAN ; Min Seob SONG ; Hyoung Doo LEE ; Kee Soo HA ; Sejung SOHN ; Young Mi HONG ; Gi Young JANG ; Jong Keuk LEE ;
Korean Circulation Journal 2019;49(1):99-108
BACKGROUND AND OBJECTIVES: Patients with Kawasaki disease (KD) are clinically heterogeneous because its diagnosis is based solely on clinical observation and there are no definitive biomarkers. We dissected the clinical heterogeneity of KD patients using the KD-associated genetic variants. METHODS: We performed a genetic association analysis in several KD subgroups categorized by clinical characteristics using the KD-associated variants of the B lymphoid tyrosine kinase (BLK; rs6993775) and Fc gamma receptor II a (FCGR2A; rs1801274) in a large number of case (n=1,011) and control (n=4,533) samples. RESULTS: BLK and FCGR2A were very significantly associated with KD in Korean KD patients (odds ratio [OR],1.48; p=4.63×10⁻¹¹ for BLK, and OR, 1.26; p=1.42×10⁻⁴ for FCGR2A). However, in KD subgroup analysis, we found that neither BLK nor FCGR2A were associated with either incomplete Kawasaki disease (iKD) type patients or those older than 5 years of age (p>0.2), suggesting that patients with iKD or those older than 5 years of age are a unique subgroup of KD. In genetic association analysis after excluding iKD patients and those older than 5 years old, we found that BLK was associated with all KD subgroups, whereas FCGR2A was specifically associated with male KD patients younger than 1 year of age (OR, 2.22; p=2.35×10⁻⁵). CONCLUSIONS: KD is a clinically and genetically heterogeneous disease. These findings will provide new insights into the clinical and genetic heterogeneity of KD.
Biomarkers
;
Diagnosis
;
Genetic Heterogeneity
;
Genome-Wide Association Study
;
Humans
;
Male
;
Mucocutaneous Lymph Node Syndrome
;
Polymorphism, Single Nucleotide
;
Population Characteristics
;
Protein-Tyrosine Kinases
9.Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
Gyu HUR ; Min Seob SONG ; Sejung SOHN ; Hyoung Doo LEE ; Gi Beom KIM ; Hwa Jin CHO ; Kyung Lim YOON ; Chan Uhng JOO ; Myung Chul HYUN ; Chul Ho KIM
Korean Circulation Journal 2019;49(2):183-191
BACKGROUND AND OBJECTIVES: We investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens. METHODS: Between March 2010 and February 2017, 16 hospitals participated in this study. A total of 102 (32.3±19.9 months, 72 males) who received infliximab at any time after first IVIG treatment failure were enrolled. Data were retrospectively collected using a questionnaire. RESULTS: Subjects were divided into two groups according to the timing of infliximab administration. Early treatment (group 1) had shorter fever duration (10.5±4.4 days) until infliximab infusion than that in late treatment (group 2) (16.4±4.5 days; p < 0.001). We investigated the response rate to infliximab and the incidence of significant CAA (z-score >5). Overall response rate to infliximab was 89/102 (87.3%) and the incidence of significant CAA was lower in group 1 than in group 2 (1/42 [2.4%] vs. 17/60 [28.3%], p < 0.001). CONCLUSIONS: This study suggests that the early administration of infliximab may reduce the incidence of significant CAA in patients with IVIG-resistant KD. However, further prospective randomized studies with larger sample sizes are required.
Aneurysm
;
Coronary Vessels
;
Fever
;
Humans
;
Immunoglobulins
;
Immunoglobulins, Intravenous
;
Incidence
;
Infliximab
;
Korea
;
Mucocutaneous Lymph Node Syndrome
;
Prospective Studies
;
Retrospective Studies
;
Sample Size
;
Treatment Failure
10.Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
Gyu HUR ; Min Seob SONG ; Sejung SOHN ; Hyoung Doo LEE ; Gi Beom KIM ; Hwa Jin CHO ; Kyung Lim YOON ; Chan Uhng JOO ; Myung Chul HYUN ; Chul Ho KIM
Korean Circulation Journal 2019;49(2):183-191
BACKGROUND AND OBJECTIVES:
We investigated the status of infliximab use in intravenous immunoglobulin (IVIG)-resistant Kawasaki disease (KD) patients and the incidence of coronary artery aneurysms (CAAs) according to treatment regimens.
METHODS:
Between March 2010 and February 2017, 16 hospitals participated in this study. A total of 102 (32.3±19.9 months, 72 males) who received infliximab at any time after first IVIG treatment failure were enrolled. Data were retrospectively collected using a questionnaire.
RESULTS:
Subjects were divided into two groups according to the timing of infliximab administration. Early treatment (group 1) had shorter fever duration (10.5±4.4 days) until infliximab infusion than that in late treatment (group 2) (16.4±4.5 days; p < 0.001). We investigated the response rate to infliximab and the incidence of significant CAA (z-score >5). Overall response rate to infliximab was 89/102 (87.3%) and the incidence of significant CAA was lower in group 1 than in group 2 (1/42 [2.4%] vs. 17/60 [28.3%], p < 0.001).
CONCLUSIONS
This study suggests that the early administration of infliximab may reduce the incidence of significant CAA in patients with IVIG-resistant KD. However, further prospective randomized studies with larger sample sizes are required.

Result Analysis
Print
Save
E-mail